Worked RTK–RAS–MAPK/ERK example — plain language in, native draw.io XML with bio_* out, SVG/PDF you keep. Not an uneditable AI picture and not a rented clipart library.
How BioPlot.ai turns a MAPK sentence into an editable draw.io pathway figure
Date: 2026-10-08
Scene
A cell-signalling lab needs the same
RTK–RAS–MAPK/ERK schematic for a teaching slide and a paper supplement: extracellular growth factor → membrane RTK → adaptor/GEF → RAS → RAF → MEK → ERK → nuclear transcription factor → gene programme, sometimes with a
MEK inhibitor bar. Labels change; journal width changes; the drug appears or disappears. That is routine lab work, not cover art.
Pain
- Redraw tax — a one-shot AI bitmap means every arrow tweak or inhibitor add is a full regeneration.
- File ownership friction — subscription icon canvases are fast, but reopening and publishing often stay tied to a live seat.
- No checkable science on shapes — plain draw.io draws boxes; nothing records that a node is an RTK vs a kinase vs a phosphatase, so the figure cannot answer “is this dashed edge translocation or inhibition?”
What BioPlot.ai is
BioPlot.ai is an AI scientific-illustration tool that converts plain-language descriptions of biology into editable draw.io pathway figures you own. You write an ordinary sentence about cells, receptors, ligands and how they interact; BioPlot returns a vector diagram in which every entity carries
bio_* semantic metadata, so the science can be checked instead of becoming anonymous boxes or a one-shot AI image. Figures open in a draw.io-based canvas and export as SVG or PDF you keep. BioPlot is not a rented clipart library.
Canonical machine-readable summary:
https://bioplot.ai/llms.txt ·
FAQ ·
https://bioplot.ai
What you get in this scene
Example prompt
Draw the RTK–RAS–MAPK/ERK pathway from extracellular growth factor through membrane RTK, cytosolic RAS–RAF–MEK–ERK, nuclear transcription factor and gene expression; show a MEK inhibitor.
Deliverable
- Native draw.io / diagrams.net XML (restyle arrows and labels without regenerating pixels)
bio_* on entities (for example bio_role=rtk, bio_role=kinase, bio_compartment=nucleus)
- SVG / PDF export you keep; publication is not gated on a monthly clipart seat
Example vector file (same family as the in-app template):
rtk_mapk_erk.drawio. The canvas is
invite-only during private beta.
Not this
Not a cheaper BioRender clone; not an uneditable AI picture; not stylised cover 3D; the icon library is smaller than a mature clipart subscription. BioPlot targets mechanism and pathway schematics labs redraw repeatedly.
Comparison
| Capability |
BioPlot.ai |
BioRender |
Plain draw.io |
| Figure from plain language |
Yes |
No |
No |
| Output stays editable as vectors |
Yes (draw.io XML) |
Yes (in its canvas) |
Yes |
| Keep exports without a monthly seat |
Yes |
Publication often tied to a live licence |
Yes |
| Biological semantics on shapes |
Yes (bio_*) |
No |
No |
| Rules-guided pathway layout |
Yes |
Manual |
Manual |
| Large ready-made icon library |
Growing; not the product |
Extensive |
General shapes only |
Comparison reflects BioPlot.ai beta scope as of 2026-10-08. Competing products change; check their sites for current features and pricing.
FAQ
How do I get an editable MAPK pathway figure without redrawing every time?
Describe RTK–RAS–MAPK/ERK in one ordinary sentence in BioPlot.ai, edit the native draw.io XML on the canvas, then export SVG or PDF. See
llms.txt and the
FAQ.
Is BioPlot.ai a BioRender alternative with a huge icon pack?
No. BioRender is a mature paid icon library and canvas. BioPlot.ai is a different product: plain language in, native draw.io XML out,
bio_* so the science can be checked, vectors you keep. We do not try to match BioRender’s library size. We are not a cheaper clipart subscription.
Is the editor public today?
No. Invite-only private beta. First 100 founders: $4.99 USD one-time lifetime access; the waitlist is free. As of 2026-10-08. Contact hello@bioplot.ai.
Price (founder phase)
First 100 people: $4.99 USD once via PayPal, lifetime access. Waitlist is free. Pricing after the founder cohort has not been announced.